Table 2 Baseline statistics of clinical data of follow-up ESCC patients.
Neoadjuvant chemotherapy (chemo group) | Neoadjuvant immunotherapy combined chemotherapy (immuno group) | P-value | |
|---|---|---|---|
Number, N | 62 | 102 | |
Gender, N (%) | 0.285 | ||
Male | 51 (36.2%) | 90 (63.8%) | |
Female | 11 (47.8%) | 12 (52.2%) | |
Age, N (%) | 0.126 | ||
> 60 | 38 (43.2%) | 50 (56.8%) | |
≤60 | 24 (31.6%) | 52 (68.4%) | |
Weight, N (%) | 0.437 | ||
> 70 | 7 (38.9%) | 11 (61.1%) | |
≤70 | 16 (29.1%) | 39 (70.9%) | |
missing | 39 (42.9%) | 52 (57.1%) | |
T stage, N (%) | 0.138 | ||
T3 | 43 (44.3%) | 54 (55.7%) | |
T2 | 1 (16.7%) | 5 (83.3%) | |
T1 | 18 (31%) | 40 (69%) | |
missing | 0 | 3 (100%) | |
N stage, N (%) | 0.827 | ||
N0 | 21 (34.4%) | 40 (65.6%) | |
N1 | 21 (42.9%) | 28 (57.1%) | |
N3 | 8 (40%) | 12 (60%) | |
N2 | 12 (36.4%) | 21 (63.6%) | |
Missing | 0 | 1 (100%) | |
Differentiated degree, N (%) | |||
poorly differentiation | 4 (33.3%) | 8 (66.7%) | |
medium-low differentiation | 16 (40.7%) | 29 (59.3%) | |
medium differentiation | 35 (35.6%) | 51 (64.4%) | |
high differentiation | 1 (33.3%) | 2 (66.7%) | |
missing | 6 (33.3%) | 12 (66.7%) | |
Pathological stage, N (%) | 0.769 | ||
I | 8 (39.1%) | 19 (60.9%) | |
II | 18 (29.6%) | 28 (70.4%) | |
III | 28 (40.6%) | 41 (59.4%) | |
IV | 8 (42.1%) | 11 (57.9%) | |
missing | 0 | 3 (100%) | |
Recurrence and metastasis, N (%) | 0.208 | ||
no | 60 (39.5%) | 92 (60.5%) | |
yes | 2 (16.7%) | 10 (83.3%) | |
Survival, N (%) | 0.890 | ||
no | 17 (34%) | 33 (66%) | |
yes | 25 (35.2%) | 46 (64.8%) | |
missing | 20 (46.5%) | 23 (53.5%) |
